Les comorbidités influencent-elles le traitement par immunotoxines ?
Oui, les comorbidités peuvent affecter la tolérance et l'efficacité des immunotoxines.
ComorbiditésTolérance au traitementEfficacité thérapeutique
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Immunotoxines : Questions médicales les plus fréquentes",
"headline": "Immunotoxines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Immunotoxines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-01",
"dateModified": "2025-04-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Immunotoxines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Noxas",
"url": "https://questionsmedicales.fr/mesh/D009676",
"about": {
"@type": "MedicalCondition",
"name": "Noxas",
"code": {
"@type": "MedicalCode",
"code": "D009676",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.888.569"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Immunotoxines",
"alternateName": "Immunotoxins",
"code": {
"@type": "MedicalCode",
"code": "D000922",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ira Pastan",
"url": "https://questionsmedicales.fr/author/Ira%20Pastan",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States."
}
},
{
"@type": "Person",
"name": "Raquel Ibáñez-Pérez",
"url": "https://questionsmedicales.fr/author/Raquel%20Ib%C3%A1%C3%B1ez-P%C3%A9rez",
"affiliation": {
"@type": "Organization",
"name": "Apoptosis, Immunity and Cancer Group, Aragón Health Research Institute (IIS-Aragón), University of Zaragoza, 50009 Zaragoza, Spain."
}
},
{
"@type": "Person",
"name": "Patricia Guerrero-Ochoa",
"url": "https://questionsmedicales.fr/author/Patricia%20Guerrero-Ochoa",
"affiliation": {
"@type": "Organization",
"name": "Apoptosis, Immunity and Cancer Group, Aragón Health Research Institute (IIS-Aragón), University of Zaragoza, 50009 Zaragoza, Spain."
}
},
{
"@type": "Person",
"name": "Alberto Anel",
"url": "https://questionsmedicales.fr/author/Alberto%20Anel",
"affiliation": {
"@type": "Organization",
"name": "Apoptosis, Immunity and Cancer Group, Aragón Health Research Institute (IIS-Aragón), University of Zaragoza, 50009 Zaragoza, Spain."
}
},
{
"@type": "Person",
"name": "Tapan K Bera",
"url": "https://questionsmedicales.fr/author/Tapan%20K%20Bera",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Emerging trends in immunotoxin targeting cancer stem cells.",
"datePublished": "2022-06-16",
"url": "https://questionsmedicales.fr/article/35718257",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.tiv.2022.105417"
}
},
{
"@type": "ScholarlyArticle",
"name": "Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH.",
"datePublished": "2023-08-25",
"url": "https://questionsmedicales.fr/article/37626430",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12967-023-04210-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment.",
"datePublished": "2023-06-26",
"url": "https://questionsmedicales.fr/article/37509078",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/biom13071042"
}
},
{
"@type": "ScholarlyArticle",
"name": "From Immunotoxins to Suicide Toxin Delivery Approaches: Is There a Clinical Opportunity?",
"datePublished": "2022-08-23",
"url": "https://questionsmedicales.fr/article/36136517",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/toxins14090579"
}
},
{
"@type": "ScholarlyArticle",
"name": "Designing a humanized immunotoxin based on DELTA-stichotoxin-Hmg2a toxin: an in silico study.",
"datePublished": "2022-11-18",
"url": "https://questionsmedicales.fr/article/36400988",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00894-022-05389-0"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions toxiques",
"item": "https://questionsmedicales.fr/mesh/D004786"
},
{
"@type": "ListItem",
"position": 4,
"name": "Noxas",
"item": "https://questionsmedicales.fr/mesh/D009676"
},
{
"@type": "ListItem",
"position": 5,
"name": "Immunotoxines",
"item": "https://questionsmedicales.fr/mesh/D000922"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Immunotoxines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Immunotoxines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-28",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Immunotoxines",
"description": "Comment diagnostiquer une maladie ciblée par immunotoxines ?\nQuels tests sont utilisés pour évaluer l'efficacité des immunotoxines ?\nLes immunotoxines sont-elles testées en essais cliniques ?\nQuels biomarqueurs sont associés aux immunotoxines ?\nComment évaluer la toxicité des immunotoxines ?",
"url": "https://questionsmedicales.fr/mesh/D000922#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Immunotoxines",
"description": "Quels symptômes peuvent indiquer une réaction aux immunotoxines ?\nLes immunotoxines provoquent-elles des effets secondaires ?\nComment reconnaître une allergie aux immunotoxines ?\nLes symptômes varient-ils selon le type d'immunotoxine ?\nQuels signes indiquent une efficacité des immunotoxines ?",
"url": "https://questionsmedicales.fr/mesh/D000922#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Immunotoxines",
"description": "Peut-on prévenir les effets secondaires des immunotoxines ?\nY a-t-il des mesures préventives avant le traitement ?\nComment minimiser les risques d'allergies aux immunotoxines ?\nLes patients doivent-ils être informés des risques ?\nQuelles sont les recommandations pour les patients sous immunotoxines ?",
"url": "https://questionsmedicales.fr/mesh/D000922#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Immunotoxines",
"description": "Comment les immunotoxines sont-elles administrées ?\nLes immunotoxines sont-elles combinées avec d'autres traitements ?\nQuel est le mécanisme d'action des immunotoxines ?\nLes immunotoxines sont-elles efficaces contre tous les cancers ?\nQuels sont les protocoles de traitement avec immunotoxines ?",
"url": "https://questionsmedicales.fr/mesh/D000922#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Immunotoxines",
"description": "Quelles complications peuvent survenir avec les immunotoxines ?\nComment gérer les complications liées aux immunotoxines ?\nLes complications sont-elles prévisibles ?\nLes complications varient-elles selon le patient ?\nQuels signes indiquent une complication grave ?",
"url": "https://questionsmedicales.fr/mesh/D000922#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Immunotoxines",
"description": "Quels facteurs augmentent le risque d'effets secondaires ?\nLes antécédents familiaux influencent-ils le risque ?\nLe mode de vie affecte-t-il le risque d'effets indésirables ?\nLes interactions médicamenteuses sont-elles un facteur de risque ?\nLes comorbidités influencent-elles le traitement par immunotoxines ?",
"url": "https://questionsmedicales.fr/mesh/D000922#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une maladie ciblée par immunotoxines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests d'imagerie, des biopsies et des marqueurs tumoraux."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité des immunotoxines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de réponse tumorale, des analyses sanguines et des examens d'imagerie sont utilisés."
}
},
{
"@type": "Question",
"name": "Les immunotoxines sont-elles testées en essais cliniques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont souvent évaluées dans des essais cliniques pour leur sécurité et efficacité."
}
},
{
"@type": "Question",
"name": "Quels biomarqueurs sont associés aux immunotoxines ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les biomarqueurs tumoraux spécifiques peuvent indiquer la réponse aux immunotoxines."
}
},
{
"@type": "Question",
"name": "Comment évaluer la toxicité des immunotoxines ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La toxicité est évaluée par des tests de laboratoire et des suivis cliniques réguliers."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une réaction aux immunotoxines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des nausées, des vomissements ou des réactions cutanées peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les immunotoxines provoquent-elles des effets secondaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme fatigue, fièvre et douleurs peuvent se manifester."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une allergie aux immunotoxines ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, démangeaisons ou gonflements peuvent signaler une allergie."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type d'immunotoxine ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la cible et de la toxine utilisée."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une efficacité des immunotoxines ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une réduction de la taille de la tumeur ou une amélioration des symptômes sont des signes."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les effets secondaires des immunotoxines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments préventifs et un suivi médical peuvent aider à réduire les effets secondaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives avant le traitement ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des évaluations de santé et des tests allergiques peuvent être effectués avant le traitement."
}
},
{
"@type": "Question",
"name": "Comment minimiser les risques d'allergies aux immunotoxines ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un historique médical complet et des tests cutanés peuvent aider à identifier les risques."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils être informés des risques ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une information claire sur les risques et bénéfices est essentielle avant le traitement."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations pour les patients sous immunotoxines ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients doivent suivre les conseils médicaux et signaler tout effet indésirable rapidement."
}
},
{
"@type": "Question",
"name": "Comment les immunotoxines sont-elles administrées ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont généralement administrées par voie intraveineuse dans un cadre clinique."
}
},
{
"@type": "Question",
"name": "Les immunotoxines sont-elles combinées avec d'autres traitements ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent être combinées avec la chimiothérapie ou la radiothérapie pour plus d'efficacité."
}
},
{
"@type": "Question",
"name": "Quel est le mécanisme d'action des immunotoxines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles ciblent spécifiquement les cellules malades en délivrant une toxine qui les détruit."
}
},
{
"@type": "Question",
"name": "Les immunotoxines sont-elles efficaces contre tous les cancers ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, leur efficacité dépend du type de cancer et des caractéristiques des cellules tumorales."
}
},
{
"@type": "Question",
"name": "Quels sont les protocoles de traitement avec immunotoxines ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les protocoles varient selon le type de cancer et incluent des cycles de traitement spécifiques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les immunotoxines ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des infections, des réactions allergiques ou des lésions organiques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux immunotoxines ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut des soins symptomatiques et parfois l'arrêt temporaire du traitement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles prévisibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être anticipées, mais d'autres peuvent survenir de manière imprévisible."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon le patient ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent varier en fonction de la santé générale et des antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication grave ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des douleurs thoraciques, des difficultés respiratoires ou des saignements doivent alerter."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'effets secondaires ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé, des antécédents d'allergies et des maladies préexistantes peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies peuvent augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque d'effets indésirables ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut réduire le risque d'effets indésirables liés aux traitements."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses sont-elles un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines interactions médicamenteuses peuvent augmenter le risque d'effets secondaires."
}
},
{
"@type": "Question",
"name": "Les comorbidités influencent-elles le traitement par immunotoxines ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les comorbidités peuvent affecter la tolérance et l'efficacité des immunotoxines."
}
}
]
}
]
}
Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, People's Republic of China; Jecho Laboratories, Inc., 7320 Executive Way, Frederick MD21704, USA. Electronic address: jianweiz@sjtu.edu.cn.
Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Vanak Sq. Molasadra St., P.O. Box 19395-5487, Tehran, Iran.
Department of Pharmacology, School of Pharmacy, Fujian Provincial Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University, Fuzhou 350122, China.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
2021-01-21
Department of Pharmacology, School of Pharmacy, Fujian Provincial Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University, Fuzhou 350122, China. Electronic address: jmxie@fjmu.edu.cn.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
2021-01-21
Cancer stem cells (CSCs) are self-renewing multipotent cells that play a vital role in the development of cancer drug resistance conditions. Various therapies like conventional, targeted, and radiothe...
Immunotoxins are antibody-toxin conjugates that bind to surface antigens and exert effective cytotoxic activity after internalization into tumor cells. Immunotoxins exhibit effective cytotoxicity and ...
In the current study, we used 32A9 and 42A1, two anti-GPC3 antibodies with similar antigen-binding capabilities and internalization rates, to construct scFv-mPE24 immunotoxins and evaluated their in v...
Although 32A9 and 42A1 had similar antigen binding capacities and internalization rates, 32A9 scFv-mPE24 had superior antitumor activity compared to 42A1 scFv-mPE24. We found that 32A9 scFv-mPE24 exhi...
These results showed that a low pH-sensitive antibody-based immunotoxin degraded faster in lysosomes, caused effective free toxin release, and led to improved cytotoxicity compared to an immunotoxin b...
Immunotoxins (ITXs) are chimeric molecules that combine the specificity of a targeting domain, usually derived from an antibody, and the cytotoxic potency of a toxin, leading to the selective death of...
Suicide gene therapy is a relatively novel form of cancer therapy in which a gene coding for enzymes or protein toxins is delivered through targeting systems such as vesicles, nanoparticles, peptide o...
Breast cancer remains the most frequently diagnosed cancer and the principal cause of mortality by malignancy in women. HER2 positive subtype includes 15-20% of breast cancer cases. This receptor coul...
LMB-100 is a novel immune-conjugate (immunotoxin) that targets mesothelin. A phase 1/2 clinical trial was conducted (NCT02810418) with primary objectives assessing the safety and efficacy of LMB-100 ±...
The use of bacterial toxins as antitumor agents has received considerable attention. Immunotoxins based on antigen recognition of single-chain antibodies have been widely explored for cancer therapy. ...
Cetuximab is a monoclonal antibody blocking the epidermal growth factor receptor (EGFR) in metastatic colorectal cancer (mCRC). However, cetuximab treatment has no clinical benefits in patients affect...
Human epidermal growth factor receptor 2 (HER2) is overexpressed on the surface of some kinds of cancer cells including breast cancer. In this study, we designed and produced a novel immunotoxin consi...
The three-dimensional (3D) structure of the fusion protein (anti-HER IT) was predicted by MODELLER 9.23 and its interaction with HER2 receptor was assessed using HADDOCK web server. Anti-HER2 IT, anti...
In-silico studies showed that (EAAAK)2 linker can efficiently prevent the formation of salt bridges between two functional domains and the constructed fusion protein has a high affinity to HER2 recept...
This novel immunotoxin has the potential to be applied as a therapeutic candidate for HER2-targeted cancer therapy. However further in vitro and in vivo evaluations are still required to confirm the e...
Targeted tumor therapy is an attractive approach for cancer treatment. Delta-like ligand 4 (DLL4) is overexpressed in tumor vasculature and plays a pivotal role in tumor neovascular development and an...